Ottobock stock backs Blue Arbor RESTORE clinical expansion

Ottobock is extending its strategic exposure to neuromuscular prosthetic control after Blue Arbor Technologies announced a 10.5 million US-dollar Series A financing on Wednesday, October 28, 2026. The round was led by Ottobock, according to Business Wire.

The financing supports completion of feasibility studies and preparations for an Investigational Device Exemption from the U.S. Food and Drug Administration. Blue Arbor plans to use the regulatory path for U.S. clinical studies of the RESTORE External Sensing Unit and will begin developing a fully implantable Internal Sensing Unit.

RESTORE adds a clinical pathway

RESTORE is designed to enable independent and simultaneous control of a prosthesis' fingers, wrist and elbow. Blue Arbor said feasibility work includes a successful second-in-human procedure with the external sensing unit at the Medical University of Vienna, bringing completed human implantations to two.

A further development is the selection of RESTORE for a University of Michigan clinical study funded by an NIH UG3 grant. The study will compare surface electrodes with implanted electrodes for prosthetic control. RESTORE has also received FDA Breakthrough Device Designation and entered the FDA's Total Product Life Cycle Advisory Program pilot.

Ottobock stock traded at 48.55 euros on Lang & Schwarz at 16:07:04 CEST on Friday, October 30, 2026.

Investors can follow the real-time quote of Ottobock stock.

German equities remain the relevant market setting for investors assessing Ottobock's corporate developments; current DAX market coverage provides the broader index context.

More news and analyses on Ottobock stock will track further clinical, regulatory and financing developments around RESTORE.